Abstract:Objective To research the curative effect and adverse reactions of bortezomib in the treatment of newly diagnosed and relapsed or refractory multiple myeloma(MM).Methods Thirty-two patients including 21 newly diagnosed multiple myeloma patients and 11 relapsed or refractory multiple myeloma(RRMM)patients.Twenty-one patients were treated with BTD regimen,it consisted of bortezomib(1.0-1.3 mg/m2) by rapid intravenous injection on the 1 st,4 th,8 th and 11th day,and dexamethasone 20 mg/d by intravenous drip(day 1-4) or 10 mg/d by intravenous drip(day 1-4,day 9-12,day 17-20),and oral thalidomide (100-200 mg/d) was given for the whole course.Nine patients received BD regimen,usage as same as the former.Two patients were treated with PAD regimen,adriamycin(9 mg/m2) was used on dayl-4,other usage as same as the former.All regimen were repeated,every 21 days as one cycle.Response to Bortezommib was assessed according to the criteria of European Group for Blood and Marrow Transplantation,and adverse reaction were evaluated according to the criteria of National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.The prognosis factors were analysed by chi-square test and Spearman rank correlation.Results The total clinical response(CR + nCR + PR + MR) was 90.6％,newly diagnosed patients compared with RRMM patients,the difference was significant (P =0.27).The total better response (CR + nCR + PR) was 71.8 ％,compared the two groups,the difference was significant (P =0.04).The total complete response (CR) was 71.8％,the difference was significant between the two groups (P =0.12).The total near complete response(CR + nCR) was 56.2％,the difference was significant between the two groups (P =0.03).The correlation coefficient of course and remission level was 0.60,the difference was significant (P ＜ 0.01).The major adverse events during treatment were blood hypocellular(56％),gastrointestinal disorder (49％),peripheral neuropathy (32％),systemic symptom (27％).Three patients got herpes zoster and one got rash.Conclusions Bortezomib based chemotherapy was well tolerated and effective in treatment of multiple myeloma,even newly diagnosed or RRMM patients.

Bortezomib induced acute lung injury in multiple myeloma patients:clinical characteristics, diagnosis and treatment

High Incidence of Varicella Herpes Zoster with Use of Bortezomib in Chinese Patients.

Efficacy And Safety Of Bortezomib Based Regimens Retreatment In Relapsed Multiple Myeloma Patients: Results From A Retrospective Study.

Bortezomib-Induced Multiple Organ Failure: Report Of Two Cases And Review Of Literature

Bortezomib in treatment of relapsing and refractory multiple myeloma

Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Adverse Effects in Treatment of Multiple Myeloma with Bortezomib Combined Regimen

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma

Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients

Bortezomib-based Vs Non-Bortezomib-based Post-Transplantation Treatment in Multiple Myeloma Patients: a Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Multi‐Omic Analysis Reveals the Impact of Bortezomib in Hyperleukocytic Acute Myeloid Leukemia

Improvement of survival in patients with newly diagnosed multiple myeloma treated by Bortezomib based chemotherapy

Clinical research of bortezomib based chemotherapeutic regimen for multiple myeloma

Clinical efficacy of modified bortezomib-based combination therapy treating Multiple myeloma

Clinical analysis of domestic bortezomib in treatment of multiple myeloma

Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review

Bortezomib Plus Chemotherapy for the Treatment of Newly Diagnosed Patients with Multiple Mye-Loma

[Bortezomib-Based Chemotherapy for Patients with Multiple Myeloma: a Single Center Experience].

Clinical efficacy and safety of domestic bortezomib in treatment of patients with multiple myeloma

Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy

Effects of Bortezomib on the Prognosis of the Newly-Diagnosed Multiple Myeloma Patients with Renal Impairment